Relay Therapeutics (Relay Therapeutics) Interest Expense : $0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Relay Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Relay Therapeutics's interest expense for the three months ended in Dec. 2023 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Relay Therapeutics's Operating Income for the three months ended in Dec. 2023 was $ -94.26 Mil. Relay Therapeutics's Interest Expense for the three months ended in Dec. 2023 was $ 0.00 Mil. GuruFocus does not calculate Relay Therapeutics's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Relay Therapeutics Interest Expense Historical Data

The historical data trend for Relay Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relay Therapeutics Interest Expense Chart

Relay Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

Relay Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Relay Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Relay Therapeutics (NAS:RLAY) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Relay Therapeutics's Interest Expense for the three months ended in Dec. 2023 was $0.00 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-94.26 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $48.50 Mil.

Relay Therapeutics's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

GuruFocus does not calculate Relay Therapeutics's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Relay Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.

Relay Therapeutics (Relay Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relay Therapeutics Inc (NAS:RLAY) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

399 Binney Street, 2nd Floor, Cambridge, MA, USA, 02139

Website

https://www.relaytx.com

Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).

Executives

Peter Rahmer	officer: See remarks	C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, 2ND FLOOR, CAMBRIDGE MA 02139
Thomas Catinazzo	officer: Vice President, Finance	C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139
Donald A Bergstrom	officer: See Remarks	840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Brian Adams	officer: General Counsel	750 LEXINGTON AVENUE, NEW YORK NY 10022
Sanjiv Patel	director, officer: President and CEO	C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139
Andy Porter	officer: See Remarks	C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139
Mark Murcko	director	C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139
Sekar Kathiresan	director	500 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Third Rock Ventures Iii, L.p.	10 percent owner	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Jami Rubin	director	C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139
Douglas S Ingram	director	2525 DUPONT DR, IRVINE CA 92612
Third Rock Ventures Gp Iv, L.p.	10 percent owner	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Svf Pauling (cayman) Ltd	10 percent owner	27 HOSPITAL ROAD, GEORGE TOWN, GEORGE TOWN E9 KY1-9008
Picularium, Llc	10 percent owner	1166 AVENUE OF THE AMERICAS, NINTH FLOOR, NEW YORK NY 10036
Laura Shawver	director	1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518